Henry Pelish Biography and Net Worth

Insider of Nuvalent

Henry is a multidisciplinary scientist skilled in cancer biology, chemical biology and organic synthesis. He contributed to the creation of Nuvalent and joined full-time in 2018.

Henry’s career has spanned multiple industry and academic appointments. Prior to joining Nuvalent, Henry was a group leader in the laboratory of Professor Matthew Shair at Harvard University. In that role, he built and led a team that discovered a new target, mechanism of action and therapeutic opportunity for treatment of acute myeloid leukemia. In parallel, he spearheaded a drug discovery program that culminated in a licensing deal and research agreement between Harvard and Merck in 2016, and subsequently served as a member of the Harvard-Merck Joint Research Committee.

Henry earned a PhD in Chemistry from Harvard University and is an avid runner and swimmer.

What is Henry E. Pelish's net worth?: The estimated net worth of Henry E. Pelish is at least $3.04 million as of September 16th, 2024. Dr. Pelish owns 33,300 shares of Nuvalent stock worth more than $3,035,961 as of November 20th. This net worth approximation does not reflect any other assets that Dr. Pelish may own. Learn More about Henry E. Pelish's net worth.
How do I contact Henry E. Pelish?: The corporate mailing address for Dr. Pelish and other Nuvalent executives is , , . Nuvalent can also be reached via phone at 857-357-7000 and via email at [email protected]. Learn More on Henry E. Pelish's contact information.
Has Henry E. Pelish been buying or selling shares of Nuvalent?: Henry E. Pelish has not been actively trading shares of Nuvalent within the last three months. Most recently, Henry E. Pelish sold 32,795 shares of the business's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $98.92, for a transaction totalling $3,244,081.40. Following the completion of the sale, the insider now directly owns 33,300 shares of the company's stock, valued at $3,294,036. Learn More on Henry E. Pelish's trading history.
Who are Nuvalent's active insiders?: Nuvalent's insider roster includes Alexandra Balcom (CFO), Emily Conley (Director), Andrew Hack (Director), Deborah Miller (insider), Darlene Noci (insider), Henry Pelish (Insider), James Porter (CEO), Matthew Shair (Director), and Christopher Turner (Insider). Learn More on Nuvalent's active insiders.
Are insiders buying or selling shares of Nuvalent?: During the last year, insiders at the sold shares 45 times. They sold a total of 3,575,429 shares worth more than $312,854,115.90. The most recent insider tranaction occured on October, 31st when CFO Alexandra Balcom sold 10,000 shares worth more than $891,900.00. Insiders at Nuvalent own 12.5% of the company. Learn More about insider trades at Nuvalent.
Information on this page was last updated on 10/31/2024.

Henry E. Pelish Insider Trading History at Nuvalent

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/16/2024	Sell	32,795	$98.92	$3,244,081.40	33,300
8/23/2024	Sell	10,500	$85.08	$893,340.00	66,095

Henry E. Pelish Buying and Selling Activity at Nuvalent

Nuvalent Company Overview

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $91.17

$90.28

$92.22

50 Day Range

MA: $97.43

$81.68

$112.17

2 Week Range

Now: $91.17

$58.80

$113.51

Volume

264,769 shs

Average Volume

534,697 shs

Market Capitalization

$5.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.